Screening mAbs with Recombinant Lectins and Ion Mobility Spectrometry

· Ion Mobility,Lectins,mAbs

Accelerated drug development requires a new way to screen glycoproteins. IonDX Inc. hasdeveloped a bench-top analytical system to address this need. Our patented atmosphericpressure ion mobility spectrometer, IMgenius™, along with recombinant prokaryotic lectin (RPL) reagents, quantifies specific glycans and binding efficiency.

• Platform technology – 3 min assay• Improved specificity over plant-based lectins • Mobility shifts reveal subpopulations • Minimum sample preparation • Detection of surface glycans

The recent global pandemic has highlighted the impact of nucleic acid-based modalities.Messenger RNA (mRNA) and double stranded DNA plasmids are being used in emerginggene and cell therapies. Large sized nucleic acid moieties remain challenging to analyzeusing traditional LC-MS techniques due to structural heterogeneity, ionization anddetection limitations. IonDX™ has developed a bench-top atmospheric pressure ion mobility spectrometer, IMgenius™ to address such challenges. This patented technology was used to profile native mRNA and DNA constructs ranging in sizes from 320kD to 2.83MDa.

All Posts

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!